Icalziss

Calcium chloride dihydrate, the active ingredient in Icalziss, is a calcium supplement/electrolyte presented as a sterile solution for extracorporeal use. It provides calcium ions to maintain extracellular calcium concentration and supports calcium balance during dialysis, plasma exchange, and cardiac surgery procedures.

GNH USA supplies Icalziss as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch.

Icalziss is employed to correct calcium deficits and maintain electrolyte balance in clinical situations that involve extracorporeal circulation. - Hemodialysis: restores calcium levels to prevent hypocalcemia during the treatment. - Plasma exchange: supplies calcium ions to maintain coagulation and electrolyte homeostasis. - Cardiac surgery with cardiopulmonary bypass: stabilizes calcium concentration to support myocardial function. - Hyperparathyroidism postoperative management: provides controlled calcium replacement when rapid shifts occur.

Calcium chloride dihydrate may be associated with several adverse reactions, most of which are related to rapid changes in serum calcium levels.

Common Side Effects: - Transient hypercalcemia: temporary elevation of serum calcium that usually resolves after infusion. - Local infusion site irritation: redness or discomfort at the catheter entry point. - Mild hypotension: slight drop in blood pressure during rapid administration. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Severe hypercalcemia: marked elevation of calcium that can cause cardiac arrhythmias. - Cardiac arrhythmias: irregular heart rhythms, including ventricular tachycardia. - Vascular calcification: deposition of calcium in blood vessels with prolonged exposure. - Anaphylactic reaction: rare severe allergic response requiring immediate treatment.

When using Icalziss, careful clinical monitoring and appropriate patient selection are essential to minimize risks. - Baseline calcium assessment: measure serum ionized calcium before initiating therapy. - Continuous monitoring: check calcium levels and cardiac rhythm during infusion. - Renal impairment adjustment: reduce dose or extend infusion time in patients with reduced kidney function. - Hypercalcemia avoidance: do not administer to patients with existing elevated calcium levels. - Concomitant digitalis caution: monitor for enhanced cardiac effects when used with digoxin. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Calcium chloride dihydrate can affect the activity of several medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Calcium channel blockers: may potentiate hypotensive effects. - Bisphosphonates: calcium can reduce absorption and efficacy of bisphosphonate therapy. - High‑dose vitamin D: combined use may precipitate severe hypercalcemia.

Moderate Interactions (Monitor Closely): - Loop diuretics: increase renal calcium loss, necessitating closer calcium monitoring. - Magnesium sulfate: concurrent administration can alter calcium balance and require dose adjustments.